Skip to content

Circulating Levels of Irisin in Healthy Young Subjects

Circulating Irisin in Healthy Young Men and Women and Correlation With Lean Body Mass, Fat Mass and Adipocytokines. Circadian and Seasonal Variation and the Effect of Food Intake and Exercise

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01986530
Acronym
IRISSAS
Enrollment
122
Registered
2013-11-18
Start date
2013-11-30
Completion date
2015-01-31
Last updated
2015-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Subjects

Keywords

irisin, adiponectin, leptin, lean body mass, fat mass

Brief summary

Irisin, a newly discovered myokine induced in exercise, has potential effects in stimulating adipose tissue browning, fighting obesity and diabetes. No prior study has reported on the role of circulating irisin in healthy individuals in correlation with lean and fat body mass. Furthermore, the circadian and seasonal variation of irisin is largely unknown.

Detailed description

The main aims of this prospective study will be to investigate: 1) circulating irisin levels in healthy, young men and women according to their lean and fat mass; 2) the circadian variations of irisin levels; 3) the seasonal variations of irisin levels.

Interventions

DIETARY_SUPPLEMENTBoost

After an overnight fast, blood samples will be obtained before as well as 30 min after standardized mixed meal ingestion

OTHERAerobic exercise

After an overnight fast and rest, blood samples will be obtained before as well as 30 min after aerobic exercise

Sponsors

424 General Military Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 25 Years
Healthy volunteers
Yes

Inclusion criteria

Healthy volunteers

Exclusion criteria

i) body mass index (BMI) above 30 or below 20 kg/m2; ii) diseases that could affect muscle or fat homeostasis; iii) medications that could affect muscle or fat homeostasis.

Design outcomes

Primary

MeasureTime frameDescription
irisin circadian variation1 day20 participants will be hospitalized and closely monitored for 24 hours. A catheter will be inserted in a vein and blood samples will be obtained every 3 hours through the 24-hour period
Irisin postprandial1 dayA sub-population of 40 participants of the cohort will receive a standardized meal (Boost) in two different quantities (20 participants will receive 125 ml and 20 participants 250 ml). Serum irisin levels will be measured at baseline and 30 min postprandial.
Irisin after excercise1 dayA sub-population of 20 participants of the cohort will be subjected to 30 min of aerobic exercise. Serum irisin levels will be measured at baseline and at 30 min.
Irisin1 dayAfter a standardized dinner and an overnight fast, a blood sample will be obtained the next morning.
irisin seasonal variation12 months20 participants will be monitored for one year and blood samples will be obtained every 3 months (at the middle of month January - April - July - October). At the same intervals physical examination and BMI calculation will be conducted. Subjects will be instructed to maintain their normal exercise routine and dietary habits.

Secondary

MeasureTime frameDescription
serum adipokines1 dayAfter a standardized dinner and an overnight fast, a blood sample for adiponectin and leptin will be obtained the next morning.
Irisin associates1 dayAfter a standardized dinner and an overnight fast, a blood sample for adiponectin and leptin will be obtained the next morning, and body composition (total body fat mass and bone-free lean mass) will be assessed by BIA. Participants will also be asked to complete a validated questionnaire assessing their diet and exercise habits. Correlations between serum irisin levels and the above parameters will be examined

Countries

Greece

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026